The DOI matches its Crossref record.
Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting.
Abstract
PURPOSE: To determine the maximum-tolerated doses (MTD), the principal toxicities, and the pharmacologic behavior of high doses of Taxol (paclitaxel; Bristol-Myers Squibb, New York, NY) combined with cisplatin and granulocyte colony-stimulating factor (G-CSF). PATIENTS AND METHODS: Untreated and minimally pretreated solid-tumor patients received 24-hour infusions of Taxol on day 1 followed by cisplatin on day 2 and G-CSF, 5 micrograms/kg/d subcutaneously (SC), beginning on day 3. Treatment was repeated every 3 weeks. Starting doses of Taxol and cisplatin were 135 and 75 mg/m2, respectively. RESULTS: The development of a severe peripheral neuropathy and/or severe myalgias precluded the chronic administration of Taxol and cisplatin with G-CSF at doses greater than 250 mg/m2 and 75 mg/m2, respectively. At this dose, the mean Taxol steady-state plasma concentration (Css) exceeds concentrations capable of inducing pertinent antimicrotubule effects in vitro. The severity of the neuropathy was related to the cumulative dose of Taxol, the magnitude of the dose administered during each treatment, and the presence of a pre-existing medical disorder associated with peripheral neuropathy. A proximal myopathy of modest severity also was documented. Although severe neutropenia occurred frequently, especially at the MTD, it was rarely associated with fever (8% of courses), and absolute neutrophil counts (ANCs) less than 500/microL never persisted for more than 5 days. Responses were noted in non-small-cell lung cancer (NSCLC) and head and neck, breast, and esophageal cancers. CONCLUSION: Taxol and cisplatin doses of 250 mg/m2 and 75 mg/m2, respectively, can be administered repetitively with G-CSF to untreated and minimally pretreated patients. However, these doses are not recommended for patients with pre-existing neuropathies until additional experience in high-risk patients is obtained. Although this Taxol dose is nearly 85% higher than the dose that can be combined with cisplatin in the absence of G-CSF, this high-dose regimen should not be used outside the investigational setting until a dose-response relationship has been demonstrated for Taxol in randomized clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Rowinsky, E. K., & Donehower, R. C. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504133321507 · Cited by 1,924
Self-citationFilgrastim (r-metHuG-CSF): the first 10 years
Welte, K., Gabrilove, J., Bronchud, M., Platzer, E., & Morstyn, G. (1996) · Blood · doi:10.1182/blood.v88.6.1907.bloodjournal8861907 · Cited by 599
Bonomi, P., Kim, K., Fairclough, D., Cella, D., Kugler, J., Rowinsky, E., Jiroutek, M., & Johnson, D. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.3.623 · Cited by 589
Self-citationChemotherapy-induced peripheral neurotoxicity (CIPN): An update
Argyriou, A. A., Bruna, J., Marmiroli, P., & Cavaletti, G. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.04.012 · Cited by 568
Hamaguchi, T., Matsumura, Y., Suzuki, M., Shimizu, K., Goda, R., Nakamura, I., Nakatomi, I., Yokoyama, M., Kataoka, K., & Kakizoe, T. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602479 · Cited by 565
Metadata
- Authors
- Rowinsky, E. K., Chaudhry, V, Forastiere, A. A., Sartorius, S. E., Ettinger, D. S., Grochow, L. B., Lubejko, B. G., Cornblath, D. R., & Donehower, R. C.
- Venue
- Journal of Clinical Oncology
- Published
- 1993-10
- Volume
- 11
- Issue
- 10
- Pages
- 2010-2020
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2102551452
- Cited by
- 192
- References
- 0
- FWCI
- 5.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. https://app.cochat.ai/papers/10.1200/jco.1993.11.10.2010
- The paper
- Rowinsky, E. K., Chaudhry, V, Forastiere, A. A., Sartorius, S. E., Ettinger, D. S., Grochow, L. B., Lubejko, B. G., Cornblath, D. R., & Donehower, R. C. (1993). Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1993.11.10.2010
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.